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Abstract
Background: Despite progress in adjuvant chemotherapy in the recent decades, pancreatic and colon cancers remain
common causes of death worldwide. Bacterial toxins, which specifically bind to cell surface-exposed glycosphingolipids, are
a potential novel therapy. We determined the expression of globotriaosylceramide (Gb3Cer/CD77), the Shiga toxin receptor,
in human pancreatic and colon adenocarcinomas.
Methodology/Principal Findings: Tissue lipid extracts of matched pairs of cancerous and adjacent normal tissue from 21
pancreatic and 16 colon cancer patients were investigated with thin-layer chromatography overlay assay combined with a
novel mass spectrometry approach. Gb3Cer/CD77 was localized by immunofluorescence microscopy of cryosections from
malignant and corresponding healthy tissue samples. 62% of pancreatic and 81% of colon adenocarcinomas showed
increased Gb3Cer/CD77 expression, whereas 38% and 19% of malignant pancreas and colon tissue, respectively, did not,
indicating an association of this marker with neoplastic transformation. Also, Gb3Cer/CD77 was associated with poor
differentiation (G.2) in pancreatic cancer (P=0.039). Mass spectrometric analysis evidenced enhanced expression of
Gb3Cer/CD77 with long (C24) and short chain fatty acids (C16) in malignant tissues and pointed to the presence of
hydroxylated fatty acid lipoforms, which are proposed to be important for receptor targeting. They could be detected in
86% of pancreatic and about 19% of colon adenocarcinomas. Immunohistology of tissue cryosections indicated tumor-
association of these receptors.
Conclusions/Significance: Enhanced expression of Gb3Cer/CD77 in most pancreatic and colon adenocarcinomas prompts
consideration of Shiga toxin, its B-subunit or B-subunit-derivatives as novel therapeutic strategies for the treatment of these
challenging malignancies.
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Introduction
Pancreatic and colon cancers are the fourth and second most
frequent causes of cancer mortality in the Western world,
respectively, accounting for estimated 84,250 deaths in 2008 in
the U. S. alone [1]. With a median survival period of about 6
months and 5-year survival rates,5% pancreatic cancer ranks
among the most lethal of the common tumors. The prognosis for
patients suffering from colon carcinomas with distant metastasis at
the time of diagnosis is almost as poor as for pancreatic cancer [2].
Only about 10–15% of the pancreatic cancer patients are
candidates for potentially curative surgery [3,4], underlining the
urgent need to develop novel strategies to treat patients with these
unresectable tumors. Targeted therapies, for example, based on
bacterial and plant toxins or monoclonal antibodies, which
recognize cell surface glycosphingolipids (GSLs), that are overex-
pressed in pancreas and/or colon cancer, might prove to be
promising approaches for adjunct therapy after surgery [5–9].
GSLs, consisting of a hydrophilic oligosaccharide chain and a
hydrophobic ceramide membrane anchor [10], are expressed as
integral constituents of lipid rafts in the outer leaflet of the plasma
membrane [11]. Besides their involvement in cell growth
regulation and cell adhesion [12], cell surface-exposed oligosac-
charide chains of GSLs ‘‘serve’’ as attachment sites for bacteria
[13] and are exploited by different toxins, including Shiga toxins
(Stxs), for surface binding, intracellular trafficking, and signalling
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6813events [14]. Stxs (also termed verotoxins), which are produced
from pathogenic Escherichia coli strains [15–19], belong to the AB5
family of bacterial toxins. They consist of an enzymatically active
A-subunit that inhibits protein biosynthesis by modifying host
rRNA and a nontoxic homopentameric B-subunit [20,21]. The B-
pentamer binds to its preferential GSL receptor globotriaosylcer-
amide (Gb3Cer/CD77) and triggers internalization of the AB5-
Gb3Cer complex by receptor mediated endocytosis via clathrin-
coated vesicles [22] or by endocytic routes that do not involve
clathrin-coated pits [23]. The toxin-receptor complex undergoes
retrograde transport through the Golgi network to the endoplas-
mic reticulum. After retro-translocation into the cytosol [24], one
molecule of the proteolytically processed A1-subunit can inhibit
protein synthesis and kill a cell.
Aberrant expression of GSLs occurs in almost all human and
animal cancers [12,25] and many tumor-associated antigens are
now known to be GSLs. Increased expression of the Stx-receptor
Gb3Cer/CD77 has been reported on various solid tumors such as
ovarian [26] and breast cancer [27] or malignant meningioma
[28]. Recently, enhanced expression of Gb3Cer/CD77 has been
described as correlating with the development of metastasis in
colon cancer [9,29]. Gb3Cer/CD77 also enables tumor-specific
plasma membrane localization of proteins (e. g. Hsp70) [30]. As
cell surface molecules, tumor-associated GSLs are accessible to
antibodies or GSL-binding toxins (i.e., Stx), making them
candidate targets for oncological applications [31]. Consequently,
the Stx-ligand Gb3Cer/CD77 is currently under investigation as a
potential target candidate for toxin-based therapeutics
[28,29,32,33].
In this study we analyzed pancreatic and colon cancer tissue for
the expression of Gb3Cer/CD77, using thin-layer chromatogra-
phy (TLC) of GSL extracts from tissues and immunohistological
staining of tissue cryosections. Enhanced expression of Stx-
receptors was detectable in most pancreatic and colon cancer
tissues, respectively, indicating an association with neoplastic
transformation. Furthermore, structural modifications of the lipid
anchors of tumor-associated Gb3Cer/CD77 species were detected
in cancerous tissues of both tumor kinds employing a novel mass
spectrometry approach combined with TLC immunodetection
[8,34]. Thus, enhanced expression and lipid alterations of
Gb3Cer/CD77 in carcinomas render this target a promising
candidate for Stx and/or Stx-constructs in oncological applica-
tions of both pancreas and colon malignancies.
Materials and Methods
Ethics Statement
The Local Ethical Committee of the Medical Council of
Westfalen-Lippe and the Medical Faculty of the University
Hospital Mu ¨nster (Mu ¨nster, Germany) approved the current
study (reference number 1IXHai). All patients were informed and
consented in writing.
Surgical Specimens
The study was performed using samples of pancreatic (n=21)
and colon (n=16) adenocarcinomas from patients who had
undergone surgery for their primary tumors [5]. Tumor histology
was determined following the criteria of the UICC [35]. The
clinicopathologic characteristics of the cohort of patients with the
carcinomas are described in Supplementary Tables S1 and S2.
Tumor specimens were snap frozen in liquid nitrogen immediately
after surgical intervention and stored at 280uC until analyzed.
Corresponding control specimens were obtained from the same
patient at the same organ site without macroscopic tumor
involvement that was confirmed by histological examination.
Preparation of Lipid Extracts from Surgical Specimens
Tissues were homogenized and extracted twice with 2 mL of
chloroform/methanol (1/2, v/v), 2 mL of chloroform/methanol
(1/1, v/v), and 2 mL of chloroform/methanol (2/1, v/v). The
combined supernatants of each tissue extract (12 mL) were dried
by rotary evaporation and phospholipids were saponified by
incubation in 4 mL of aqueous 1 N NaOH for 1 h at 37uC. After
neutralization with 400 mL of 10 N HCl, the samples were
dialyzed against deionized water and dried by rotary evaporation.
The extracts were adjusted to defined volumes of chloroform/
methanol (2/1, v/v) corresponding to 0.1 mg wet weight per mL.
Purification of Stx1
Stx1 was purified from E. coli C600(H19J) carrying the stx1 gene
from E. coli O26:H11 strain H19 [36]. Briefly, bacteria were
disintegrated by sonication and extracted with polymyxin B
(3000 U/ml) (Sigma-Aldrich Chemie GmbH, Taufkirchen, Ger-
many). After centrifugation, the supernatant containing crude Stx1
was concentrated by ultrafiltration and subjected to chromatog-
raphy on hydroxylapatite column followed by chromatofocusing
[37]. The column fractions containing Stx1 were pooled, dialyzed
and aliquots were stored at 270uC until use. Purity of the Stx1
preparation was monitored by SDS-PAGE, and the structural
integrity of the toxin was checked by peptide mapping employing
mass spectrometry [21]. Biological activity was determined by
Vero cell cytotoxicity [38].
Anti-Gb3Cer/CD77 and Anti-Stx1 Antibodies
The preparation and specificity of polyclonal chicken anti-
Gb3Cer/CD77 antibody recognizing the Gala1-4Galb1-4Glc-
residue of Gb3Cer/CD77 species has been described [39,40]. Stx1
was detected with the mouse IgG1 monoclonal anti-Stx1 antibody
109/4-E9b (Sifin, Berlin, Germany).
High-performance Thin-layer Chromatography (TLC) and
Reference GSLs
A mixture of neutral GSLs from human erythrocytes, consisting
of monohexosylceramide, lactosylceramide, Gb3Cer/CD77, and
globotetraosylceramide (Gb4Cer), was used as reference [40] for
TLC antibody and Stx1 overlay assays. The nomenclature of
GSLs follows the IUPAC-IUBM recommendations 1997 [41].
Reference GSLs and tissue lipid extracts were applied to glass-
backed silica gel 60 precoated high-performance thin-layer
chromatography (TLC) plates (no. 1.05633.0001; Merck, Darm-
stadt, Germany) with an automatic applicator (Linomat IV,
CAMAG, Muttenz, Switzerland) and separated in chloroform/
methanol/water (120/70/17, each by vol., with 2 mM CaCl2).
Reference GSLs were stained with orcinol.
TLC Overlay Assay
Gb3Cer/CD77 was detected using the overlaid polyclonal
chicken antibody or Stx1 as described [40,42]. Primary anti-
Gb3Cer/CD77 and secondary alkaline phosphatase-labeled
antibodies (Dianova, Hamburg, Germany) were used in 1:2000
dilutions. Bound secondary antibodies were visualized by color
development with 0.05% (w/v) 5-bromo-4-chloro-3-indolylpho-
sphate p-toluidine salt (BCIP, no. 6368.3; Roth, Karlsruhe,
Germany). The immunostained chromatograms were washed
with glycine buffer and stored at 220uC. Blue immunopositive
Gb3Cer/CD77-bands were quantified with a CD60 scanner
Tumor-Associated Gb3Cer/CD77
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R, version
1.06.000). Gb3Cer/CD77 amounts were determined semiquanti-
tatively as relative expression compared with reference GSLs. The
secondary densitometric data (see ‘‘Statistical Analysis’’ below)
were used to define 4 categories of tumor expression compared to
the normal tissues by formal cut-point analysis: high overexpres-
sion (category I, 4000,x), moderate overexpression (category II,
700,x,4000), equal expression (category III, 2700,x,700),
and lowered expression (category IV, x,2700) for pancreas
carcinoma and high overexpression (category I, 2000,x),
moderate overexpression (category II, 200,x,2000), equal
expression (category III, 2200,x,200), and lowered expression
(category IV, x,2200) for colon carcinoma, respectively.
Immunohistochemistry
Immunocytochemical staining was conducted as described [8].
Briefly, cryosections (4 mm) were incubated with the anti-Gb3Cer/
CD77 antibody (1:15) and an anti-CD31 antibody (1:200) (mouse
IgG1, clone MEM-05, Immunotools, Friesoythe, Germany).
Antibodies binding to Gb3Cer/CD77 and CD31 were detected
with dichlorotriazinylamino fluorescein (DTAF)-labeled anti-
chicken-IgY antibody (Dianova) and Alexa Fluor 568-conjugated
anti-mouse-IgG antibody (Invitrogen, USA, CA), diluted 1:40 and
1:250, respectively. For negative controls, immunohistochemistry
was performed using chicken preimmune serum and irrelevant
mouse IgG1 antibody (Immunotools). Nuclear DNA of the cells
was stained with 49,6-diamidine-2-phenylindole-dihydrochloride
(DAPI, Sigma-Aldrich, USA). Fluorochrome-labeled antibodies
and DAPI-stained nuclei were evaluated under a fluorescence
microscope (Axioskop, Zeiss, Jena, Germany), original magnifica-
tion640 (objective lense Plan-Neofluar, numerical aperture 0.75),
following published protocols [43]. To confirm the hydrophobic
nature of the target of the anti-Gb3Cer/CD77 antibodies, lipids
were extracted with methanol and chloroform/methanol (1/1, v/
v) from the mounted sections prior to staining.
Infrared Matrix-assisted Laser Desorption/Ionization
Orthogonal Time-of-Flight (IR-MALDI-o-TOF) Mass
Spectrometry
The specifications of the IR-MALDI-o-TOF mass spectrometer
(MDS Sciex, Concord, Ontario, Canada) and direct TLC-IR-
MALDI-MS-analysis from immunopositive bands of the Stx1
TLC overlay assay have been detailed by Distler et al. [34]. GSLs
were analyzed in the positive ion mode using glycerol as matrix.
Statistical Analysis
Primary densitometric data of immunostained Gb3Cer/CD77
bands and secondary densitometric data, obtained from difference
values of matched pairs calculated by subtracting normal from
related tumor tissue values, were compiled with the software
package SPSS, version 14.0.2 (SPSS Inc., Chicago, IL) for
nonparametric statistical analysis. The sign test was used for the
set of primary densitometric data to examine the significance of
relationship between Gb3Cer/CD77 expression and neoplastic
transformation. The median test was performed for primary and
secondary densitometric data to test whether Gb3Cer/CD77-
expression was significantly different among the tumors compris-
ing various clinicopathologic categories. Correlation coefficients
were calculated for ranked values of the primary densitometric
data of normal and tumor tissues, respectively, and the ranked
difference values. Kendall’s t was used to assess the degree of
association between Gb3Cer/CD77-expression and histopatho-
logical grading. All tests were two tailed and awas set at 0.05.
Results
We probed tissue from 21 pancreatic and 16 colon adenocar-
cinoma patients for expression of Stx-receptor Gb3Cer/CD77 (for
structure see Figure 1). For this purpose, crude lipid extracts and
cryosections from postoperative matched pairs of malignant versus
adjacent unaffected tissues from the same patients were analyzed
by means of TLC overlay technique and immunofluorescence
microscopy. To gain further structural details of tumor-associated
modifications of Gb3Cer/CD77 species, a novel mass spectrom-
etry approach was employed that combines TLC immunodetec-
tion with IR-MALDI-o-TOF-MS [8,34]. The wet weights of the
investigated cancerous and healthy tissues and the corresponding
pathology data are listed in Supplementary Tables S1 and S2.
TLC Immunodetection of Tumor-Associated Gb3Cer/
CD77 in Pancreas and Colon Cancer
Identical aliquots of crude lipid extracts of matched pairs from
neoplastic and corresponding unaffected tissues were subjected
simultaneously to TLC, followed by TLC overlay detection of
Gb3Cer/CD77 using Stx1 and the anti-Gb3Cer/CD77 antibody.
Positive bands were ranked according to the different expression of
Gb3Cer/CD77; rank 1 indicates the highest intensity (Table 1).
Based on densitometry, tumors were grouped into four categories:
ranging from high (I), and moderate (II) overexpression, equal
(III), and lowered expression (IV).
Pancreatic Cancers. Figure 1A shows four single
representative Stx1 TLC overlay stains of tumor and related
healthy tissue extracts, each representing one of the four categories
of pancreatic cancers. In total, 61.9% of the investigated
pancreatic carcinomas showed moderate to high overexpression
of Gb3Cer/CD77, whereas 14.3% exhibited equal and 23.8%
diminished Gb3Cer/CD77 expression levels (see Table 1).
Globotetraosylceramide (Gb4Cer), known as ‘‘low affinity’’
ligand of Stx1, was undetectable in pancreatic tumors and
adjacent normal tissues using Stx1 as detection tool. TLC
immunostains employing the polyclonal anti-Gb3Cer/CD77
antibody were similar in findings to those obtained with the Stx1
TLC overlay assays showing little higher sensitivity in tracing of
Gb3Cer/CD77-species (see Supplementary Figure S1A).
Colon Cancers. Figure 1B shows three single representative
Stx1 TLC overlay stains of colonic cancer matched pairs, each
representing one of the three categories verified in colonic cancers.
Gb3Cer/CD77 was moderately to highly overexpressed in 81.3%
of malignant versus healthy colon tissues. None of the colon tumors
exhibited equal expression resulting in vacant category III. Less
Gb3Cer/CD77 was detected in 18.8% of the tumor tissue (see
Table 1). As in pancreatic tissues, Gb4Cer was undetectable in
colon tumors and adjacent normal tissues using Stx1 as detection
tool. The parallel TLC immunostains employing the polyclonal
anti-Gb3Cer/CD77 antibody are shown in Supplementary Figure
S1B.
Immunohistochemical Detection of Tumor-Associated
Gb3Cer/CD77 in Pancreas and Colon Cancer
Binding of anti-Gb3Cer/CD77 antibody to frozen sections of
pancreas and colon carcinoma tissues and to corresponding
healthy tissues of the same patients was monitored histochemically.
Sections were co-immunostained with an antibody against the
endothelial cell marker CD31, and cell nuclei were visualized with
DAPI fluorochrome.
For example, extensive antibody binding to pancreatic tumor
cells (T) was detected for patient 18 (tumor category I) as shown in
Figure 2A. In contrast, little or no Gb3Cer/CD77 was found in
Tumor-Associated Gb3Cer/CD77
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6813Figure 1. TLC overlay assay detection of tumor-associated Gb3Cer/CD77 in pancreas (A) and colon cancer (B). Aliquots from crude
lipid extracts equivalent to 2 mg tissue wet weight of normal (N) and tumor tissue (T) were simultaneously separated by TLC. Neutral GSLs from
human erythrocytes served as positive reference in the overlay assay (R, 10.8 mg) and the orcinol stain (O, 16.0 mg). The synopsis of Gb3Cer/CD77-
expression in cancerous tissues of both tumor entities is provided in Table 1, and the histopathological data of pancreas and colon carcinomas are
summarized in Supplementary Tables S1 and S2, respectively. Representative examples of pancreas (A) and colon cancers (B) of tumor categories I to
IV are shown. None of the investigated colon carcinomas was found with equal expression of Gb3Cer/CD77 in adjacent normal tissue (B). Thus,
category III remained vacant in the cohort of patients. C, structure of Stx1 receptor Gb3Cer (d18:1, C16:0). The ceramide (Cer) lipid anchor
preferentially appears in healthy human tissues with C24 or C16 fatty acid but constant sphingosine (d18:1).
doi:10.1371/journal.pone.0006813.g001
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blood vessels, known to carry Gb3Cer/CD77 [21,39,43], showed
also positive staining in pancreatic malignant tissue.
Immunohistochemical comparisons demonstrate high Gb3Cer/
CD77 expression levels in colon tumors (T) as exemplified for
patient 13, Figure 2B. In contrast, adjacent normal tissue (N) from
the same patient lacked Gb3Cer/CD77. Angiogenesis seems to be
advanced in some investigated colon cancers as evidenced by
CD31 and Gb3Cer/CD77 positive endothelial cells within the
tumor mass.
Control sections incubated with mouse IgG1 isotype controls as
well as with chicken preimmune serum did not stain. After GSL
extraction of the tissues, Gb3Cer/CD77 was no longer detectable
with the antibody (data not shown).
Structural Characterization of Tumor-Associated Gb3Cer/
CD77 in Pancreas and Colon Cancer
The Stx1 positive bands of TLC-separated lipid extracts were
directly analyzed on the TLC plates by TLC-IR-MALDI-MS as
described [34]. Mass spectra were acquired in the positive ion
mode and all Gb3Cer/CD77 species were detected as singly
charged monosodiated molecular ions.
Pancreatic Cancers. Combined Stx1 detection and TLC-
IR-MALDI-MS demonstrate individual compositional changes of
overexpressed Gb3Cer/CD77 species in neoplastic compared to
unaffected pancreatic tissue (e.g., patient 19 (tumor category I),
Figure 3). Analyzing the upper of the Stx1 positive triple band of
the tumor (T, left panel, inset), most abundant [M3*+Na]
+
molecular ions point to the presence of Gb3Cer (d18:1/d18:0,
C24:0) with saturated d18:0 sphinganine besides the more
common monounsaturated d18:1 sphingosine (sphingenine). The
same holds for the minor [M2*+Na]
+ and [M1*+Na]
+ ions, which
refer to the structures of Gb3Cer (d18:1/d18:0, C23:0) and
Gb3Cer (d18:1/d18:0, C22:0), respectively. In contrast, only low
expression of Gb3Cer/CD77 could be detected in the upper Stx1
positive band of normal pancreatic tissue as shown in Figure 3 (N,
left panel). The high abundance [M4+Na]
+ ions of the lower Stx1
positive band of the tumor (T, middle panel) indicate strong
overexpression of Gb3Cer (d18:1, C16:0) in tumor tissue
compared to very low abundance ions in the corresponding
healthy tissue (N, middle panel). However, the most prominent
structural alteration was found in the lowest Stx1 positive band of
the cancerous tissue by detecting [M5*+Na]
+ ions (T, right panel),
which were undetectable in normal tissue (N, right panel). When
compared to Gb3Cer (d18:1, C16:0) (T, middle panel), the shift in
16 atomic mass units indicates hydroxylation of the ceramide
moiety that leads to the proposed structure of Gb3Cer (d18:1,
h16:0) carrying a hydroxylated C16:0 fatty acid. In addition, ions
at m/z 1064.65 indicate the presence of Gb3Cer (d18:0, h16:0).
This striking ceramide modification occurred in 85.7% of the
pancreas tumors so far investigated. A synopsis of the proposed
structures of Gb3Cer/CD77 species is provided in the
Supplementary Table S3.
Colon Cancers. Stx1 detection combined with TLC-IR-
MALDI-MS allowed us to profile the individual structures of
overexpressed Gb3Cer/CD77 species as exemplarily shown for
patient 16 in Figure 4 (T, left panel). High abundant [M3+Na]
+
ions point to Gb3Cer (d18:1, C24:1/C24:0) as the most likely
Gb3Cer/CD77 variants in the upper Stx1 positive band,
accompanied by less pronounced [M2+Na]
+ and [M1+Na]
+ ions,
which correspond to Gb3Cer (d18:1, C23:0) and Gb3Cer (d18:1,
C22:0), respectively. The same ions but with much lower
intensities were obtained from the upper Stx1 positive band of
the normal tissue (N, left panel). In the lower band of the tumor (T,
Table 1. Expression of Gb3Cer/CD77-GSLs in pancreatic and
colon carcinomas.
Pancreas cancer
Category
* % Rank
{ Grading
{ Patient
I 28.6 131 9
221 0
32 – 3 1 2
434
531 8
623
II 33.3 721 3
828
937
10 2 20
11 2 17
12 2 16
13 2 5
III 14.3 14 2 21
15 2 9
16 3 1
IV 23.8 17 2 15
18 1 2
19 X 6
20 1–2 11
21 2 14
Colon cancer
Category
* % Rank
{ Grading
{ Patient
I 18.8 126
228
321 3
II 62.5 437
531 1
621 6
72 – 3 1 5
834
921 2
10 3 1
11 2 10
12 2–3 9
13 2 5
IV 18.8 14 2 2
15 2 14
16 3 3
*Based on the secondary densitometric data, tumors were grouped into
categories I to IV corresponding to high (I) and moderate (II) overexpression,
equal (III) and lowered expression (IV).
{The 21 pancreatic tumors were ranked from 1 to 21 and the 16 colon tumors
from 1 to 16, whereby rank 1 indicates the highest, rank 2 the second highest,
etc., and the last rank the lowest expression of Gb3Cer/CD77.
{Histopathologic grading: G1, well differentiated; G2, moderately differentiated;
G3, poorly differentiated; G4, undifferentiated; GX, histopathologic grading
cannot be assessed.
doi:10.1371/journal.pone.0006813.t001
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+ ions could be assigned to the
Gb3Cer (d18:1, C16:0) structure, which is also detectable in the
normal tissue but with less ion intensity (N, middle panel). In the
lowest band [M5*+Na]
+ ions indicate the presence of the Gb3Cer
(d18:1, h16:0) variant with hydroxylated C16:0 fatty acid, which
could not be found in the normal tissue (N, right panel). This
remarkable ceramide modification was found in approximately
19% of the colon tumor TLC immunostains so far investigated. A
synopsis of the proposed structures of Gb3Cer/CD77 species is
provided in the Supplementary Table S3.
Statistical Analysis
Box plots of the primary densitometric data of TLC overlay
assay determined Gb3Cer/CD77 levels in the pancreatic (n=21
patients) and colon (n=16 patients) tissues are provided (Figure 5A
and B, respectively). Overexpression of Gb3Cer/CD77 recorded
in 81.3% of colon cancer compared to adjacent healthy tissues was
significant (P=0.021), whereas increased expression of Gb3Cer/
CD77 in 61.9% of malignant pancreatic tissues was not significant
(P=0.189). In both pancreatic and colon cancer, the presence of
Stx-detected Gb3Cer/CD77 bands did not correlate to any
Figure 2. Immunohistological detection of Gb3Cer/CD77 in cryosections of pancreas (A) and colon cancer (B). Sections of normal (N)
and tumor tissue (T) of pancreatic cancer patient 18 (A) and of colon cancer patient 13 (B) were immunostained with the anti-Gb3Cer/CD77 antibody
and coimmunostained with an antibody against the endothelial cell marker CD31. Cell nuclei were detected with DAPI. Scale bars correspond to
20 mm. Representative examples of tumors of category I are shown (see Table 1). The histopathological data of pancreas and colon carcinoma are
summarized in Supplementary Tables S1 and S2, respectively.
doi:10.1371/journal.pone.0006813.g002
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PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6813Figure 3. Tracing tumor-associated Gb3Cer/CD77 species in pancreas cancer. Lipid extracts equivalent to 2 mg wet weight of normal (N)
and tumor tissue (T) of patient 19 (tumor category I, see Table 1 and Supplementary Table S1) were simultaneously separated by TLC followed by
overlay analysis using Stx1. The Stx1 positive Gb3Cer/CD77 bands, which are marked with arrowheads in the insets, were analyzed by TLC-IR-MALDI-
MS. The prevalent [M3*+Na]
+ molecular ions of the upper band of the tumor tissue (T, left panel) correspond to Gb3Cer (d18:1/d18:0, C24:0) and the
minor ions could be assigned to Gb3Cer (d18:1/d18:0, C23:0) and Gb3Cer (d18:1/d18:0, C22:0), respectively. In the upper band of normal tissue (N, left
panel) much lower intensities of these molecular ions were observed. The high abundant [M4+Na]
+ ions of the lower band in the tumor (T, middle
panel) represent Gb3Cer (d18:1, C16:0), which is detectable only in trace quantities in normal tissue (N, middle panel). Analysis of the lowest band of
the tumor (T, right panel) revealed [M5*+Na]
+ ions, which are indicative for hydroxylated Gb3Cer (d18:1/d18:0, h16:0). This Gb3Cer/CD77 variant was
undetectable in normal tissue (N, right panel). The m/z values of molecular ions and proposed structures of Gb3Cer/CD77-variants of malignant and
adjacent normal tissues as well as references from human erythrocytes are listed in Supplementary Table S3.
doi:10.1371/journal.pone.0006813.g003
Figure 4. Tracing tumor-associated Gb3Cer/CD77 species in colon cancer. Lipid extracts equivalent to 2 mg wet weight of normal (N) and
tumor tissue (T) of patient 16 (tumor category II, see Table 1 and Supplementary Table S2) were simultaneously separated by TLC followed by overlay
analysis using Stx1. The Stx1 positive Gb3Cer bands, which are marked with arrowheads in the insets, were analyzed by TLC-IR-MALDI-MS. The
prevalent [M3+Na]
+ molecular ions of the upper band of the tumor tissue (T, left panel) correspond to Gb3Cer (d18:1, C24:1/C24:0) and the less
abundant [M2+Na]
+ and [M1+Na]
+ ions to Gb3Cer (d18:1, C23:0) and Gb3Cer (d18:1, C22:0), respectively. In the upper band of normal tissue (N, left
panel) much lower intensities of corresponding molecular ions were observed. The strong [M4+Na]
+ ions of the lower band in the tumor (T, middle
panel) represent Gb3Cer (d18:1, C16:0), which is detectable only in low quantities in normal tissue (N, middle panel). Analysis of the lowest band of
the tumor (T, right panel) revealed [M5*+Na]
+ ions, which are indicative for hydroxylated Gb3Cer (d18:1, h16:0). This Gb3Cer/CD77 variant was
undetectable in normal tissue (N, right panel). The m/z values of molecular ions and proposed structures of Gb3Cer/CD77-variants of malignant and
adjacent normal tissues as well as references from human erythrocytes are listed in Supplementary Table S3.
doi:10.1371/journal.pone.0006813.g004
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mentary Tables S1 and S2). However, for pancreatic tumors, the
difference values of Gb3Cer/CD77 expression correlate with the
grade of tumor differentiation (P=0.039, t=0.396) indicating
higher levels of Gb3Cer/CD77 in less differentiated malignancies.
This association between poor differentiation of tumors in patients
with Gb3Cer/CD77 overexpression in malignant pancreatic tissue
is depicted in the box plots of Figure 5C. In conclusion, the
expression of Gb3Cer/CD77 is greater in less differentiated
malignant tissue suggesting the Stx receptor as a potential marker
for poor differentiation of pancreatic tumors.
Discussion
By clustering in lipid raft membrane microdomains [11,44], the
oligosaccharide chains of the GSLs exhibit strong binding activities
towards their ligands [45]. Hence, tumor-associated GSLs, i.e.,
GSLs showing elevated expression in cancerous compared to
normal tissues, are perfectly suited for tumor diagnosis and
targeted anticancer therapies [31,46,47]. Consequently, antibod-
ies, lectins or toxins with GSL binding specificities have
engendered great interest in oncology. For example, two novel
monoclonal antibodies, SC104 [6] and 14F7 [48], were recently
raised against the oligosaccharide epitopes of tumor-associated
sialylated GSLs (=gangliosides) suggesting certain gangliosides as
molecular targets for antibody-based cancer immunotherapy. In
addition to monoclonal antibodies, plant and bacterial toxins that
bind to GSLs are currently under investigation for clinical
purposes. Examples are the ribosome-inactivating proteins (RIPs)
viscumin from the plant Viscum album [49], which is specific for
CD75s-gangliosides [5] and Stxs from Stx-producing E. coli
(STEC) [9,33]. Stxs, which are unique among bacterial toxins in
sharing rRNA-N-glycosidase activity with plant RIPs [50], satisfy
several principal challenges in oncology like molecular stability,
and capabilities to cross physiologic barriers, and to withstand
extracellular or intracellular degradation [32].
Stx escapes intracellular degradation after cell surface binding
and retrograde transport, which depends largely on the molecular
arrangement of GSLs in the plasma membrane. Only GSLs that
associate strongly with lipid rafts carry AB5 toxins retrogradely and
sort the toxins to the endoplasmic reticulum [51]. Although the
terminal Gala1-4Gal-disaccharide is the primary recognition
domain, the chain length of the fatty acid of the ceramide moiety
might be important not only for the affinity of Stx1 towards
Gb3Cer/CD77 [52] but also for the retrograde sorting of the toxin
[53]. A more efficient intracellular routing of Stx to the
endoplasmic reticulum occurs when the toxin is associated with
Gb3Cer/CD77 variants carrying shorter chain fatty acids
(primarily C16), which correlates with higher cellular sensitivity.
Substitution of Gb3Cer/CD77-species with longer chain fatty
acids (C22, C24) on the other hand results in retrograde transport
to the Golgi apparatus only [53]. This lipoform-dependent traffic
of Gb3Cer/CD77 from the cell surface to the endoplasmic
reticulum has been hypothesized as a new signal transduction
pathway. Importantly, most pancreatic and colon tumors showed
up-regulation of Gb3Cer/CD77-species with C16:0 fatty acids,
which supposedly correlate with augmented sensitivity to Stx1
induced cytotoxicity [53]. Interestingly, we observed additional
hydroxylation in the ceramide moiety of more than 80% of
pancreas and in ca. 20% of colon tumor derived Gb3Cer/CD77,
most likely due to biosynthesis of h16:0 fatty acid, which has
limited distribution in healthy tissues. In earlier studies hydrox-
ylated fatty acids were found prominently in association with
neoplastic transformation of human tissue in ceramides of
Figure 5. Box plots of Gb3Cer/CD77 expression in pancreas (A)
and colon (B) normal and tumor tissues. The boxes are bounded
above and below by the 25% and 75% percentiles. The lines in the
boxes and the little squares indicate the median and mean values and
the two6the minimum and maximum values, respectively. A, although
not significant (P=0.189, n=21), an enhanced expression of Gb3Cer/
CD77 could be observed in pancreatic tumors compared to normal
tissues. B, the expression of Gb3Cer/CD77 is markedly increased in
tumor colon tissues compared to that in the adjacent normal tissues
indicating an association between Gb3Cer/CD77 expression and
neoplastic transformation (*, P=0.021, n=16). C, correlation between
Gb3Cer/CD77 expression and pancreatic tumor differentiation (n=20
patients, because one tumor could not be assigned; see Table 1).
Tumors were divided into two groups according to histopathologic
grading: grade#2 (n=14 patients) and grade.2 (n=6 patients). Rank
correlation analysis of difference values points to a statistically
significant higher Gb3Cer/CD77 expression in pancreas tumors graded
as.2 (*, P=0.039, t=0.396).
doi:10.1371/journal.pone.0006813.g005
Tumor-Associated Gb3Cer/CD77
PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6813fucosylated GSLs [54,55] and the association of hydroxyl fatty
acids with ceramides containing both C18 sphingosine and C18
phytosphingosine in a Lewis
x-containing ganglioside has been
described in great detail [56]. In order to elucidate the functional
importance, Gb3Cer/CD77 fatty acid hydroxylation augments
the binding affinity of Stx [57], rendering hydroxylated Gb3Cer/
CD77 a highly efficient target for oncological purposes. An
enhanced content of Gb3Cer/CD77 carrying hydroxylated fatty
acids has been detected in ovarian carcinoma-derived cells, which
survived selectively in the presence of taxol and cisplatin. This
modification of the GSL structure occurred in association with
anticancer-drug resistance [58]. Further on another study
provided evidence for elevated levels of Gb3Cer/CD77 in primary
ovarian cancers and hypersensitivity to Stx1 of multidrug resistant
tumor-derived cell lines [26,53]. All these data suggest an
exceptionally attractive perspective for the direct targeting of
Gb3Cer/CD77-expressing tumors employing Stx or Stx-derived
constructs as a therapeutic for patients with unresectable tumors or
advanced cancer refractory to chemotherapy.
The expression of Gb3Cer/CD77 in the neovasculature
adjacent to and within the tumor has been previously observed
for primary ovarian carcinomas and their metastases [26],
astrocytomas and neuroblastomas [53]. As tumors depend on
the generation of new vasculature to proliferate, targeting
neovascular cells is another approach to inhibit tumor growth
that might ‘‘starve’’ tumors as cancer cells are deprived of blood
flow. Indeed, Lingwood et al. [53] showed the complete long-term
elimination of human astrocytoma xenografts in nude mice after
Stx1 administration. Massive apoptosis was observed in both
tumor and vascular cells within the treated xenograft, suggesting
tumor elimination not only by antineoplastic but also by
antiangiogenic activity.
Consistent with recently published data [9], we observed
increased expression of Gb3Cer/CD77 in malignant colon tissues.
However, expression was not correlated to parameters such as
tumor differentiation or stage grouping. Importantly, for pancre-
atic tumors, which exhibited markedly increased Gb3Cer/CD77
in most neoplasms (61.9%), we could determine correlation with
the grade of tumor differentiation, demonstrating a trend towards
augmented Gb3Cer/CD77 in less differentiated malignancies.
Thus, overexpression in pancreatic tumors suggests Stx receptors
as potential markers for poor differentiation in this type of cancer.
Of note, Falguie `res et al. observed that nonmetastasized and
metastasized colon tumors from Gb3Cer/CD77-positive primary
colon tumors retained their Gb3Cer/CD77 profile and binding
capacity towards the Stx B-subunit [9].
In conclusion, our studies suggest that Stx-targeting of Gb3Cer/
CD77 expressing malignancies provide an opportunity to develop
novel strategies to treat pancreatic and colon cancer. In light of
enhanced Gb3Cer/CD77 expression on human cancer cells, it is
tempting to propose the use of Stx and Stx-constructs for tumor
cell delivery purposes to aid the recovery of unresectable or
metastatic as well as chemoresistant tumors.
Supporting Information
Table S1 Pathological data of pancreatic carcinoma and wet
weights of normal and malignant tissues of the pancreas.
Found at: doi:10.1371/journal.pone.0006813.s001 (0.07 MB
DOC)
Table S2 Pathological data of colonic carcinomas and wet
weights of normal and malignant tissues of the colon.
Found at: doi:10.1371/journal.pone.0006813.s002 (0.06 MB
DOC)
Table S3 Detected molecular ions and proposed structures of
Gb3Cer/CD77 variants obtained by direct TLC-IR-MALDI-MS
from healthy and malignant tissues from pancreas and colon
together with references from human erythrocytes.
Found at: doi:10.1371/journal.pone.0006813.s003 (0.06 MB
DOC)
Figure S1 TLC overlay assay detection of tumor-associated
Gb3Cer/CD77 in pancreas (A) and colon cancer (B). Aliquots
from crude lipid extracts equivalent to 1 mg (pancreas) and 0.5 mg
tissue wet weight (colon) of normal (N) and tumor tissue (T) were
simultaneously separated by TLC and subjected to anti-Gb3Cer
antibody TLC overlay assay. Neutral GSLs from human
erythrocytes served as positive reference in the overlay assay (R,
10.8 mg) and the orcinol stain (O, 16.0 mg). Patients were assigned
to 4 tumor categories according to the different expression of
Gb3Cer/CD77 in malignant versus healthy tissues: I, high
overexpression; II, moderate overexpression; III, equal expression,
and IV, lowered expression. The synopsis of Gb3Cer/CD77-
expression in cancerous tissues of both tumor entities is provided in
Table 1, and the histopathological data of pancreas and colon
carcinomas are summarized in Supplementary Tables S1 and S2,
respectively. Representative examples of pancreas (A) and colon
cancers (B) of tumor categories I to IV are shown. None of the
investigated colon carcinomas was found with equal expression of
Gb3Cer/CD77 in adjacent normal tissue (B). Thus, category III
remained vacant in the cohort of patients.
Found at: doi:10.1371/journal.pone.0006813.s004 (6.83 MB TIF)
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